Purdue Pharma’s Strong Track Record of
Helping Address Prescription Drug Abuse and Diversion

The opioid crisis is among our nation’s top health challenges. Purdue has long been an industry leader in the fight against opioid abuse and diversion, and developing opioids with abuse-deterrent properties. 


Our series of initiatives address many important dimensions of this complex problem.  As a company, we have taken a number of significant steps toward that end:

  • We are investing in research to develop non-opioid pain medications.
  • We are delivering the US Surgeon General’s TurnTheTideRx materials, which review considerations when prescribing opioids for chronic pain, to healthcare providers.
  • We were the first pharmaceutical company to advocate that states adopt Prescription Drug Monitoring Programs (PDMPs), and we are actively promoting their use across the country.
  • We have shared the CDC Guideline for Prescribing Opioids for Chronic Pain with thousands of prescribers and pharmacists.
  • We supported the National Sheriffs’ Association (NSA) with a grant to provide front line officers with the rescue drug naloxone.
  • Purdue collaborated with the US Conference of Mayors (USCM) to provide awards to cities for the “Safeguard My Meds Prescription Drug Abuse Prevention Recognition Program” to honor outstanding initiatives that address prescription drug misuse and abuse in America’s cities.

Purdue has developed three of the ten FDA-approved opioids with abuse-deterrent properties.

  • The DEA, FDA, NIDA, and other agencies have stated that opioids with abuse-deterrent properties are making an impact but must be part of a comprehensive national strategy to address the opioid crisis that also includes prevention and treatment.
  • Approximately 90% of opioid analgesics are generic, immediate-release, and non–abuse-deterrent.1

Purdue provides law enforcement training, education, and materials to help address prescription drug abuse and diversion.

  • Our RxREACTS program provides training on abuse detection and deterrence to physicians, pharmacists, and allied healthcare professionals, and our Law Enforcement Liaison & Education (LELE) department provides similar training to law enforcement at the state and local levels.  
  • We support the National Sheriffs’ Association (NSA) with funding for a training curriculum for front-line officers and host training workshops at NSA conferences.
  • RxPATROL® (Pattern Analysis Tracking Robberies and Other Losses) is the first and only national database that tracks, analyzes, and provides information on pharmacy crime to law enforcement and retail pharmacies. Created by Purdue in May 2003, RxPATROL® now has approximately 12,000 registered users and helps law enforcement solve pharmacy crimes, and educates pharmacy owners on how they can protect themselves, their businesses, and their customers.
  • We sponsor the National Association of Drug Diversion Investigators (NADDI) Law Enforcement Grant program, which provides additional resources to law enforcement to help combat prescription drug abuse and diversion.
  • We support the Partnership for Drug Free Kid’s Medicine Abuse Project that consists of a toll-free hotline (Spanish and English) for parents to receive advice, guidance, and resources to help support their children who may be addicted to prescription drugs.

Purdue was the first pharmaceutical company to advocate for the use of PDMPs in states across the country.

  • We provided a $3 million grant to help form a private/public partnership with the Commonwealth of Virginia to enhance its PDMP and help integrate the use of its data into the regular workflow of doctors and nurses. The grant allows the Virginia Department of Health Professions to connect the state PDMP with electronic health records used by doctors and pharmacies.
  • We recently announced a partnership with Project Lazarus and Safe Kids North Carolina through the North Carolina Disposal Initiative (NCDI) by supporting state-wide medicine disposal activities as well as conducting systematic research to evaluate the impact of community-based prevention programs on opioid-related overdoses, abuse, and diversion.
  • We provided a $1 million grant to the National Association of Boards of Pharmacy (NABP) with a grant to establish PMP InterConnect, a system to help states share prescription data to help deter doctor-shopping across state lines, and is now used in over 40 states.
  • We developed the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®) System to measure rates of abuse, misuse, and diversion across the nation. RADARS® now operates as an independent, nonprofit operation of the Rocky Mountain Poison and Drug Center (RMPDC), a division of the Denver Health and Hospital Authority (DHHA). It contributes to the understanding of trends, aids in the development of effective interventions, and assists pharmaceutical companies in fulfillment of their regulatory obligations, such as risk evaluation and mitigation strategies (REMS). 

1Quintiles IMS NPA (August 2017 data) 09 13 17_Common Errors Updated_2016 data_20170925

The prescription and illicit opioid abuse crisis is a multifaceted public health challenge, and as a manufacturer of prescription opioids, we have a responsibility to join the fight. At Purdue we are committed to lead our industry in helping address our nation's prescription and illicit opioid abuse crisis.

There is more to come – as we continue to work with partners and experts to deliver solutions. Below you will find additional information about our efforts.

Read our open letter about the opioid crisis.